VP4896 (Voyager Therapeutics)

VP4896 is a sustained-release implant of leuprolide acetate, a gonadotropin-releasing hormone (GnRH) agonist, developed by Voyager Pharmaceutical Corporation for the treatment of Alzheimer's disease. The therapeutic rationale is based on the "gonadotropin hypothesis," which suggests that elevated levels of luteinizing hormone (LH) following menopause or andropause contribute to the pathogenesis of Alzheimer's disease. By continuously stimulating GnRH receptors, leuprolide induces desensitization and downregulation, leading to the suppression of the hypothalamic-pituitary-gonadal (HPG) axis and a significant reduction in LH and follicle-stimulating hormone (FSH) levels. Voyager initiated Phase 3 clinical trials to evaluate whether this hormonal suppression could stabilize cognitive function in patients with mild-to-moderate Alzheimer's disease, but the development was ultimately discontinued due to a lack of efficacy and financial constraints.

Other names

leuprolide acetate implantleuprorelin acetate